Reinnervate Expands Its Distribution Network for Alvetex® Across Europe

REINNERVATE EXPANDS ITS DISTRIBUTION NETWORK FOR ALVETEX^®
ACROSS EUROPE  

 

Sedgefield, UK. October 2011. Reinnervate, the emerging global leader in the rapidly growing 3D cell culture market, is delighted to announce it has signed agreements with seven new European distributors for the non-exclusive distribution of alvetex^®, its breakthrough 3D cell culture technology.

 

These agreements mark a significant expansion of reinnervate's distribution network. Under the terms of the new agreements, alvetex^® will be distributed and sold under the reinnervate brand by leading regional distributors of life sciences research products -  Generon (UK), Biozol GmbH (Germany), Chemie Brunschwig AG (Switzerland), THP Medical Products (Austria), In Vitro AS (Denmark), Euroclone (Italy) and Bio Connect (the Benelux region).

 

Following the recent expansion of reinnervate's distribution network in Asia and Australia the appointment of these new distributors further increases the company's global reach, enabling more researchers to directly access the multi award winning alvetex^® 3D technology platform .  

 

Richard Rowling, Commercial Director of reinnervate, commented: “The limitations of traditional cell culture techniques to generate biologically-relevant in vitro models are well documented.  Alvetex^® 3D cell culture products help to overcome these limitations and the expansion of our European sales footprint is an important step towards our goal of making it easy for customers in every country to access alvetex products, services and support.”

 

Researchers wishing to purchase alvetex^® can do via the reinnervate web portal at http://www.reinnervate.com/alvetex/order

 

About alvetex^®

 

Alvetex^® is a unique polystyrene material that provides a robust and inert scaffold for cells to grow and form complex 3D structures in the laboratory, mimicking the normal growth and formation of tissues in the body. Reinnervate has extensively tested and validated alvetex^® with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.

 

Alvetex^® has been launched globally in several formats: a 12-well culture plate, 6-well and 12-well inserts and a deep petri dish. These formats provide researchers with an exceptional degree of versatility in how they choose to construct different 3D cell culture models. Through enabling alternative applications, such as long-term 3D cell culture over several weeks, 3D cell growth at air/liquid interface and 3D cell growth with different media constituents, to be performed simply and routinely, reinnervate continues to make genuine 3D cell culture a reality for researchers today.

 

Alvetex^® was named among the winners of The Scientist magazine’s “Top 10 Life Science Innovations of 2010” and was selected among the most technologically significant of 2010 in the 49th Annual R&D100 Awards.

 

See the company video - www.reinnervate.com/company-video

 

For further information, please contact

 

For Reinnervate

Ashley Cooper, Chief Executive Officer

+44 (0)1740 625266

info@reinnervate.com

 

David Robinson

Alto Marketing

+44 (0) 1489 557672

davidr@alto-marketing

 

About reinnervate

 

Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.

 

Reinnervate’s core technology is alvetex^®, a unique and proprietary scaffold that enables routine 3D cell culture in the laboratory. Alvetex^® provides a nanoscale environment that supports genuine homogeneous 3D cell growth. Cells grown using alvetex form complex 3D tissue cultures which more closely mimic normal in-vivo cell growth and the formation of tissues in the body than conventional techniques. The use of alvetex-derived 3D cell cultures can provide researchers with greater insight into how cells behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D or other emerging 3D cell culture technologies.

 

Reinnervate has generated significant data, which have been published extensively in peer-reviewed publications, exemplifying the use of alvetex in a large number of cell types and applications. Alvetex^® has been launched globally in several formats: a 12-well culture plate, 6-well and 12-well inserts and a deep well petri dish.  

 

Reinnervate is also using its cell biology expertise to generate a library of synthetic small molecules that mediate stem cell differentiation in vitro. The first of these small molecules, ec23^®, is commercially available and offers the potential for robust and reproducible differentiation of neural cell types.

 

Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.

 

www.reinnervate.com

www.reinnervate.com/company-video